ATE434437T1 - Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen - Google Patents

Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen

Info

Publication number: ATE434437T1
Authority: AT; Austria
Prior art keywords: treatment; local; sub; musculoeskeletal; antagonists
Prior art date: 1999-02-18

Application number

AT00912469T

Other languages

English (en)

Inventor

Wolfgang Mueller

Thomas Stratz

Lothar Faerber

Original Assignee

Novasearch Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-18

Filing date

2000-02-16

Publication date

2009-07-15

1999-02-18 Priority claimed from GBGB9903761.6A external-priority patent/GB9903761D0/en

1999-06-25 Priority claimed from GBGB9914949.4A external-priority patent/GB9914949D0/en

1999-11-25 Priority claimed from GBGB9927877.2A external-priority patent/GB9927877D0/en

2000-02-16 Application filed by Novasearch Ag filed Critical Novasearch Ag

2009-07-15 Application granted granted Critical

2009-07-15 Publication of ATE434437T1 publication Critical patent/ATE434437T1/de

Links

201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
102000035037 5-HT3 receptors Human genes 0.000 title 1
108091005477 5-HT3 receptors Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 4
208000027866 inflammatory disease Diseases 0.000 abstract 2
244000052769 pathogen Species 0.000 abstract 2
230000001717 pathogenic effect Effects 0.000 abstract 2
206010003246 arthritis Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000007794 irritation Effects 0.000 abstract 1
230000003137 locomotive effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
210000002435 tendon Anatomy 0.000 abstract 1
UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 abstract 1
229960003688 tropisetron Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00912469T 1999-02-18 2000-02-16 Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen ATE434437T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9903761.6A GB9903761D0 (en)	1999-02-18	1999-02-18	Organic compounds
GBGB9914949.4A GB9914949D0 (en)	1999-06-25	1999-06-25	Special organic compounds
GBGB9927877.2A GB9927877D0 (en)	1999-11-25	1999-11-25	Special organic compounds
PCT/EP2000/001269 WO2000048581A2 (en)	1999-02-18	2000-02-16	Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases

Publications (1)

Publication Number	Publication Date
ATE434437T1 true ATE434437T1 (de)	2009-07-15

Family

ID=27269651

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00912469T ATE434437T1 (de)	1999-02-18	2000-02-16	Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen

Country Status (8)

Country	Link
US (2)	US6462065B2 (de)
EP (1)	EP1152761B1 (de)
JP (1)	JP2002537245A (de)
AT (1)	ATE434437T1 (de)
AU (1)	AU3422800A (de)
DE (1)	DE60042446D1 (de)
ES (1)	ES2327600T3 (de)
WO (1)	WO2000048581A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000048581A2 (en) *	1999-02-18	2000-08-24	Novartis Ag	Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
GB9918425D0 (en) *	1999-08-04	1999-10-06	Novartis Ag	Organic compounds
GB0216027D0 (en)	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US20040048874A1 (en) *	2001-05-22	2004-03-11	Bardsley Hazel Judith	New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
KR20050111318A (ko) *	2003-01-13	2005-11-24	다이노젠 파마세우티컬스, 인코포레이티드	기능성 장 질환을 치료하는 방법
ES2285407T3 (es) *	2003-01-13	2007-11-16	Dynogen Pharmaceuticals Inc.	Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
CA2519379A1 (en) *	2003-04-04	2004-10-21	Dynogen Pharmaceuticals, Inc.	Method of treating lower urinary tract disorders
US8470846B2 (en) *	2004-04-30	2013-06-25	National University Corporation Chiba University	Remedy for psychoneurotic diseases
WO2006105117A2 (en) *	2005-03-28	2006-10-05	Dynogen Pharmaceuticals, Inc.	Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1993542A1 (de) *	2006-03-01	2008-11-26	Galderma Research & Development, S.N.C.	Verfahren zur behandlung entzündlicher hauterkrankungen mittels tropisetron und pharmazeutische zusammensetzungen daraus
GB0701170D0 (en) *	2007-01-22	2007-02-28	Imp Innovations Ltd	Compositions and uses thereof
WO2013057554A2 (en) *	2011-10-18	2013-04-25	Helsinn Healthcare Sa	Therapeutic combinations of netupitant and palonosetron
CN104971050A (zh) *	2015-08-05	2015-10-14	青岛蓝盛洋医药生物科技有限责任公司	止吐药物盐酸托烷司琼组合物冻干粉针剂及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122528A (en) *	1983-12-22	1992-06-16	Erbamont, Inc.	Analgesic use of benzobicyclic carboxamides
EP0189002B1 (de)	1984-12-20	1993-03-03	Sandoz Ag	Behandlung von Gastrointestinalkrankheiten durch Anwendung von 5-HT3-Antagonisten
GB8701022D0 (en) *	1987-01-19	1987-02-18	Beecham Group Plc	Treatment
US5364863A (en) *	1987-09-08	1994-11-15	Eli Lilly And Company	Specific 5-HT3 antagonists
US4877798A (en) *	1987-11-23	1989-10-31	Merrell Dow Pharmaceuticals Inc.	Treatment of fibromyalgia
US5063230A (en) *	1988-11-29	1991-11-05	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents
AU642178B2 (en) *	1989-11-28	1993-10-14	Roche Palo Alto Llc	New tricyclic compounds
US5225407A (en) *	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
US5491148A (en) *	1991-04-26	1996-02-13	Syntex (U.S.A.) Inc.	Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US6048859A (en) *	1992-06-29	2000-04-11	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
GB9214184D0 (en) *	1992-07-03	1992-08-12	Smithkline Beecham Plc	Pharmaceuticals
US5378686A (en) *	1992-09-21	1995-01-03	Research Corporation Technologies, Inc.	Therapeutic treatment of fibromyalgia
GB9314174D0 (en)	1993-07-08	1993-08-18	American Home Prod	5-ht3-antagonists
IS4208A (is) *	1993-09-22	1995-03-23	Glaxo Group Limited	3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6009875A (en) *	1993-10-14	2000-01-04	Berlex Laboratories, Inc.	Use of sympathetic antagonists for treatment of chronic muscle pain
GB9406857D0 (en) *	1994-04-07	1994-06-01	Sandoz Ltd	Improvements in or relating to organic compounds
GB9418545D0 (en) *	1994-09-15	1994-11-02	Merck Sharp & Dohme	Therapeutic agents
US5576317A (en) *	1994-12-09	1996-11-19	Pfizer Inc.	NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
RU2180852C2 (ru)	1994-12-12	2002-03-27	Омерос Медикл Системс, Инк.	Ингибирующий раствор и способ подавления боли, воспаления или спазма
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
US5612051A (en) *	1995-11-17	1997-03-18	Yue; Samuel K.	Method of treating involuntary muscle dysfunction with relaxin hormone
AU3170697A (en) *	1997-05-30	1998-12-30	Minnesota Mining And Manufacturing Company	Transdermal drug delivery device for the delivery of tropisetron or granisetron
US6211171B1 (en) *	1998-05-19	2001-04-03	Dalhousie University	Use of antidepressants for local analgesia
WO2000048581A2 (en) *	1999-02-18	2000-08-24	Novartis Ag	Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
JP2002537255A (ja) *	1999-02-18	2002-11-05	ノバルティスアクチエンゲゼルシャフト	リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
AR025110A1 (es) *	1999-08-13	2002-11-06	Vela Pharmaceuticals Inc	Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
GB9923748D0 (en) *	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
US6623742B2 (en) *	2001-09-17	2003-09-23	Allergan, Inc.	Methods for treating fibromyalgia
DE10221831A1 (de) *	2002-05-16	2004-02-05	Thomas Stratz	Behandlung nicht Erreger-entzündlicher Hautkrankheiten mit 5-HT3-Rezeptor-Antagonisten

2000
- 2000-02-16 WO PCT/EP2000/001269 patent/WO2000048581A2/en not_active Ceased
- 2000-02-16 AU AU34228/00A patent/AU3422800A/en not_active Abandoned
- 2000-02-16 JP JP2000599373A patent/JP2002537245A/ja active Pending
- 2000-02-16 ES ES00912469T patent/ES2327600T3/es not_active Expired - Lifetime
- 2000-02-16 EP EP00912469A patent/EP1152761B1/de not_active Expired - Lifetime
- 2000-02-16 AT AT00912469T patent/ATE434437T1/de not_active IP Right Cessation
- 2000-02-16 DE DE60042446T patent/DE60042446D1/de not_active Expired - Lifetime
2001
- 2001-08-14 US US09/929,454 patent/US6462065B2/en not_active Expired - Lifetime
2002
- 2002-08-21 US US10/224,938 patent/US7393857B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2000048581A3 (en)	2001-01-11
DE60042446D1 (de)	2009-08-06
JP2002537245A (ja)	2002-11-05
WO2000048581A2 (en)	2000-08-24
US20020002197A1 (en)	2002-01-03
EP1152761A2 (de)	2001-11-14
US20030008809A1 (en)	2003-01-09
US6462065B2 (en)	2002-10-08
AU3422800A (en)	2000-09-04
ES2327600T3 (es)	2009-11-02
EP1152761B1 (de)	2009-06-24
US7393857B2 (en)	2008-07-01

Legal Events

Date	Code	Title	Description
2009-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
EA199700156A1 (ru)	1997-12-30	Производные индола как антагонисты рецептора 5-нт
EA200101019A1 (ru)	2002-04-25	Модуляторы рецепторов глюкокортикоидов
DE60042446D1 (de)	2009-08-06	Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
DE60038686D1 (de)	2008-06-05	Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
EA200000299A1 (ru)	2000-12-25	Лекарства
ATE435010T1 (de)	2009-07-15	Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
BRPI0417376A (pt)	2007-04-10	compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0104834A (pt)	2002-08-20	Moduladores de receptores de glucocorticóides
ATE257703T1 (de)	2004-01-15	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE69838678D1 (de)	2007-12-20	ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
PL1716152T3 (pl)	2009-01-30	Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
BR0307429A (pt)	2004-12-28	Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
DE69318854D1 (de)	1998-07-02	Spiroazacyclischderivate als substanz p antagonisten
IT1293807B1 (it)	1999-03-10	Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
DE60232029D1 (de)	2009-05-28	N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
ATE327974T1 (de)	2006-06-15	Modulatoren des glucocorticoid-rezeptors
ATE502646T1 (de)	2011-04-15	Fgfr agoniste
EA200601194A1 (ru)	2006-10-27	Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
TR199700956T1 (xx)	1998-02-21	Indazolkarboksamidler.
ATE297929T1 (de)	2005-07-15	Azabicycloalkan-derivate zur verwendung als inhibitoren der serotonin-wiederaufnahme und als 5ht2a antagonisten
ATE285794T1 (de)	2005-01-15	Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
MA26541A1 (fr)	2004-12-20	Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines
EE200100520A (et)	2002-12-16	N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
ATE255094T1 (de)	2003-12-15	Piperazinderivate zur behandlung der niedrigen harnwege
ATE182467T1 (de)	1999-08-15	Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen